Randomized comparative trial of cefpirome versus ceftazidime in the empirical treatment of suspected bacteraemia or sepsis

Journal of Antimicrobial Chemotherapy

Volumn 42, Issue 4, 1998, Pages 503-509

  Norrby, S R ^a,d   Geddes, A M ^b   Shah, P M ^c   Koch, H ^e   Valtonen, M ^e   Haenninen, P ^e   Sammalkorpi, K ^e   Nikoskelainen, J ^e   Hormila, P ^e   Hill, B ^e   Malmvall, B E ^e   Runehagen, A ^e   Hansson, C ^e   Nyman, L ^e   Burman, L ^e   Soederstrom, C ^e   Elowson, S ^e   Odenholt, I ^e   Nagler, J ^e   Degauque, C ^e   Siska, G ^e   Installe, E ^e   Huyghens, L ^e   Furcolo, F ^e   Guarino, A ^e   Vesconi, S ^e   Citterio, R ^e   Marchi, E ^e   Sabria, M ^e   Gudiol, F ^e   Bouza Santiago, E ^e   more..

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c GOETHE UNIVERSITY   (Germany)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFPIROME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; METRONIDAZOLE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SEPSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APACHE; BACTEREMIA; CEFTAZIDIME; CEPHALOSPORINS; FEMALE; HUMANS; MALE; MIDDLE AGED; SEPSIS;

EID: 0031661223     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/42.4.503     Document Type: Article

References (17)

1. Jones, R. N. (1996). Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. American Journal of Medicine 100, Suppl. 6A, 3S-12S.
2. Verbist, L. and the International Study Group. (1993). Epidemiology and sensitivity of 8625 ICU and hematology/oncology bacterial isolates in Europe. Scandinavian Journal of Infectious Diseases, Suppl. 91, 14-24.
3. Spencer, R. C. (1993). Cross-susceptibility of cefpirome and four other β-lactams against isolates from haematology/oncology in intensive-care units. Scandinavian Journal of Infectious Diseases, Suppl. 91, 25-32.
4. Bryskier, A. (1997). New concepts in the field of cephalosporins: C-3′ quaternary ammonium cephems (Group IV). Clinical Microbiology and Infection 3, Suppl. 1, S1-S6.
5. Norrby, S. R. (1993). Cefpirome efficacy in the treatment of urinary and respiratory tract infections and safety profile. Scandinavian Journal of Infectious Diseases, Suppl. 91, 41-50.
6. Norrby, S. R. & Geddes, A. M. (1993). Efficacy of cefpirome in the treatment of septicaemia. Scandinavian Journal of Infectious Diseases, Suppl. 91, 51-59.
7. Knaus, W. A., Wagner, D. P., Draper, E. A., Zimmerman, J. E., Bergner, M., Bastos, P. G. et al. (1991). The APACHE III Prognostic System. Risk prediction of hospital mortality for critically ill hospitalised adults. Chest 100, 1619-36.
8. Knaus, W. A., Harrell, F. E., Fisher, C. J., Wagner, D. P., Opal, S. M., Sadoff, J. C. et al. (1993). The clinical evaluation of new drugs for sepsis. A prospective study design based on survival analysis. Journal of the American Medical Association 270, 1233-41.
9. Bone, R. C. (1991). Sepsis, the sepsis syndrome, multi-organ failure: a plea for comparable definitions. Annals of Internal Medicine 114, 332-3.
10. National Committee for Clinical Laboratory Standards. (1995). Performance Standards for Antimicrobial Susceptibility Testing -Fifth Edition: Approved Standard M100-S5. NCCLS, Villanova, PA.
11. Whitehead, J. (1992). The Design and Analysis of Sequential Clinical Trials, 2nd edn. Ellis Horwood, New York.
12. Jones, R. N., Thornsberry, C. & Barry, A. L. (1984). In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyamino cephalosporin. Antimicrobial Agents and Chemotherapy 25, 710-18.
13. Reeves, D. S., Bywater, M. J. & Holt, H. A. (1993). The activity of cefpirome and ten other antibacterial agents against 2858 clinical isolates collected from 20 centres. Journal of Antimicrobial Chemotherapy 31, 345-62.
14. UK Intensive Care Study Group. (1992). The efficacy and tolerance of cefpirome in the treatment of severe infection in patients in intensive care. In Program and Abstracts of the Thirty-Second Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992. Abstract 1574, p. 373. American Society for Microbiology, Washington, DC.
15. Craig, W. A. (1993). The pharmacokinetics of cefpirome -rationale for a twelve hour dosing regimen. Scandinavian Journal of Infectious Diseases, Suppl. 91, 33-40.
16. Rybak, M. (1996). The pharmacokinetic profile of a new generation of parenteral cephalosporin. American Journal of Medicine 100, Suppl. 6A, 39S-44S.
17. Barriere, S. L. & Lowry, S. F. (1995). An overview of mortality risk prediction in sepsis. Critical Care Medicine 23, 376-93.